Meeting
2023 ASCO Genitourinary Cancers Symposium
Examination of resistance to nivolumab monotherapy through single-cell analysis of tumors from patients enrolled in the HCRN GU16-260 study of nivolumab monotherapy.
Authors
David A. Braun
School of Medicine, Yale University, New Haven, CT
David A. Braun , Kelly Street , Opeyemi Jegede , Neil Ruthen , Miya Hugaboom , Nicholas R Schindler , David F. McDermott , Elizabeth R. Plimack , Jeffrey A. Sosman , Naomi B. Haas , Michael E. Hurwitz , Hans J. Hammers , Sabina Signoretti , Michael B. Atkins , Catherine J. Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 698)
DOI
10.1200/JCO.2023.41.6_suppl.698
Abstract #
698
Poster Bd #
J11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study.
First Author: David A. Braun
Poster
2024 ASCO Annual Meeting
Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.
First Author: Yu Fujiwara
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Artificial intelligence (AI)-powered tumor microenvironment (TME) analysis to identify potential biomarkers for ICIs with or without bevacizumab in hepatocellular carcinoma (HCC).
First Author: Hong Jae Chon